X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (139) 139
humans (124) 124
male (91) 91
female (88) 88
middle aged (79) 79
gastroenterology & hepatology (74) 74
adult (65) 65
aged (62) 62
performing operations (51) 51
transporting (51) 51
hepatitis c virus (48) 48
chemistry (43) 43
interferon (42) 42
metallurgy (42) 42
hepatitis c (41) 41
hepatitis (37) 37
animals (36) 36
liver (36) 36
polymorphism, single nucleotide (36) 36
analysis (35) 35
genotype (35) 35
genome-wide association (34) 34
hepacivirus - genetics (34) 34
hepatitis c, chronic - drug therapy (33) 33
infection (33) 33
care and treatment (32) 32
genetic aspects (32) 32
health aspects (32) 32
human necessities (32) 32
hygiene (32) 32
medical or veterinary science (32) 32
antiviral agents - therapeutic use (31) 31
ribavirin (30) 30
treatment outcome (30) 30
chemical aspects of bandages, dressings, absorbent pads, orsurgical articles (29) 29
disinfection, sterilisation, or deodorisation of air (29) 29
materials for bandages, dressings, absorbent pads, or surgicalarticles (29) 29
methods or apparatus for sterilising materials or objects ingeneral (29) 29
virology (28) 28
chemical or physical processes, e.g. catalysis or colloidchemistry (27) 27
physical or chemical processes or apparatus in general (27) 27
their relevant apparatus (27) 27
gastroenterology (26) 26
mice (25) 25
research (25) 25
risk factors (25) 25
treatment of water, waste water, sewage, or sludge (25) 25
biological response modifiers (24) 24
hepatitis c, chronic - virology (24) 24
hepatology (24) 24
hepatocellular-carcinoma (23) 23
drug therapy, combination (22) 22
hepacivirus - drug effects (22) 22
hepatocellular carcinoma (21) 21
microbiology (21) 21
young adult (21) 21
aged, 80 and over (20) 20
medicine & public health (20) 20
patients (19) 19
prognosis (19) 19
replication (19) 19
gastroenterology and hepatology (18) 18
genetic-variation (18) 18
japan (18) 18
plus ribavirin (18) 18
antiviral agents - administration & dosage (17) 17
hepatitis c, chronic - genetics (17) 17
liver cirrhosis (17) 17
therapy (17) 17
adolescent (16) 16
alleles (16) 16
electricity (16) 16
genome-wide association study (16) 16
hcv (16) 16
japanese patients (16) 16
medical research (16) 16
medicine (16) 16
mice, scid (16) 16
ribavirin - therapeutic use (16) 16
viruses (16) 16
cirrhosis (15) 15
hepatoma (15) 15
infectious diseases (15) 15
interleukins - genetics (15) 15
liver cancer (15) 15
antiviral agents - pharmacology (14) 14
biochemistry (14) 14
development and progression (14) 14
medicine, experimental (14) 14
multidisciplinary sciences (14) 14
mutation (14) 14
amino-acid substitutions (13) 13
case-control studies (13) 13
gene frequency (13) 13
genes (13) 13
genetics & heredity (13) 13
hepatitis b (13) 13
multivariate analysis (13) 13
oncology (13) 13
science (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Journal Article
Human Genetics, ISSN 0340-6717, 7/2013, Volume 132, Issue 7, pp. 783 - 792
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 548 - 556
In Japan, daclatasvir (DCV) and asunaprevir (ASV) therapy was the first IFN-free treatment to be approved, and thousands of patients have since been... 
Ledipasvir/sofosbuvir with ribavirin | NS5A inhibitor | Daclatasvir | Retreatment | Medicine & Public Health | Resistance-associated variants | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Asunaprevir | Surgical Oncology | NS5B polymerase inhibitor | SOFOSBUVIR | DACLATASVIR PLUS ASUNAPREVIR | LEDIPASVIR | VIRUS PATIENTS | DUAL THERAPY | COMBINATION TREATMENT | CHRONIC HCV INFECTION | 1-INFECTED PATIENTS | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | GENOTYPE 1B INFECTION | Humans | Middle Aged | Fluorenes - therapeutic use | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Treatment Failure | Aged, 80 and over | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Pilot Projects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Isoquinolines - therapeutic use | Aged | Retreatment - methods | Sustained Virologic Response | Retreatment - adverse effects | Medicine, Experimental | Medical research | Care and treatment | Hepatitis C | Hepatitis C virus | Ribavirin | Cirrhosis | Hepatitis | Liver | Interferon | Ribonucleic acid--RNA | Patients | Index Medicus
Journal Article
Personality and Individual Differences, ISSN 0191-8869, 01/2018, Volume 121, pp. 193 - 199
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2011, Volume 204, Issue 1, pp. 84 - 93
Journal Article
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 06/2017, Volume 52, Issue 6, pp. 746 - 753
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2017, Volume 52, Issue 4, pp. 504 - 511
Daclatasvir and asunaprevir combination therapy has shown a high virological response for chronic genotype 1 hepatitis C virus (HCV)-infected patients.... 
Daclatasvir | Chronic hepatitis C | Medicine & Public Health | Resistance-associated variants | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Older patients | Asunaprevir | Surgical Oncology | UNITED-STATES | RIBAVIRIN | VIROLOGICAL RESPONSE | PEGINTERFERON | VIRUS GENOTYPE 1B | PLUS ASUNAPREVIR | PEGYLATED INTERFERON | NULL RESPONDERS | INFECTION | HCV | GASTROENTEROLOGY & HEPATOLOGY | Predictive Value of Tests | Isoquinolines - adverse effects | Age Factors | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | RNA, Viral - blood | Viral Load | Young Adult | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Hepacivirus - drug effects | Hepacivirus - isolation & purification | Drug Administration Schedule | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Resistance, Viral - genetics | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Aged | Polymorphism, Single Nucleotide | Sustained Virologic Response | Isoquinolines - administration & dosage | Sulfonamides - administration & dosage | Care and treatment | Analysis | Aged patients | Drug resistance | Hepatitis C virus | Hepatitis C | Health aspects | Index Medicus
Journal Article